Financials
Financial year 2025
ALSVID PHARMA from Alveringem, company number BE0797937044, closed financial year 2025 with a result of € 22,127 after tax. For that financial year ALSVID PHARMA recorded a gross margin of € 41,268 and equity of € 49,299. Compared with financial year 2024, the result moved from € 12,480 to € 22,127. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.
€ 49,299
▲ 81% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 22,127
▲ 77% vs 2024
Profit after tax over the fiscal year.
€ 109,179
▲ € 90,285 vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 46,799.
People and assets in 2025
€ 9,821
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 69,945
€ 16,458 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 48,103
▼ 32% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 9,167
▼ 19% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Gross margin | € 22,129 | € 23,840 | € 41,268 | ▲ 73% |
| Profit after taxes | € 12,193 | € 12,480 | € 22,127 | ▲ 77% |
| Equity | € 14,693 | € 27,172 | € 49,299 | ▲ 81% |
| Total debts | € 102,305 | € 154,665 | € 211,882 | ▲ 37% |
| Cash | € 15,906 | € 18,894 | € 109,179 | ▲ € 90,285 |
| Retained profit | € 12,193 | € 24,672 | € 46,799 | ▲ 90% |
| Bank debt | € 0 | € 0 | € 69,945 | |
| Balance sheet total | € 116,998 | € 181,837 | € 261,182 | ▲ 44% |
Key figures of ALSVID PHARMA, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to ALSVID PHARMA?
What happened at ALSVID PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 22,127 (▲ 77% vs 2024). Source: NBB ↗
- Jérôme Weyts became a director. NBB
- New establishment in Alveringem. KBO
- Peter Weyts became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 12,193 profit in 2023 to € 22,127 profit in 2025.
Paid € 18,527 in corporate taxes since 2023.
Best year ever: 2025, with € 22,127 profit.
Management
Behind ALSVID PHARMA are Jérôme Weyts and Peter Weyts. Peter Weyts is also behind WEYTS EQUINE VETTING.
Directors
According to the 2025 annual accounts
Jérôme Weyts
Director
since 2023
since 2023
Establishments
Establishment units
Physical locations of this company
Zavel 4
8690 Alveringem
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0797.937.044
- VAT number
- BE 0797.937.044
- Registered office
- Zavel 4, 8690 Alveringem
- Names & denominations
- ALSVID PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 2 February 2023
- Peppol
- Active · Active since 30 Dec 2025
- Activities · NACE
Vervaardiging van andere voedingsmiddelen, neg
Activiteiten van medische beeldvorming en medische laboratoria
Groothandel in farmaceutische en medische artikelen
Activiteiten van medische laboratoria